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The pandemic dissemination of KPC carbapenemase-producing Klebsiella pneumoniae (KPC-KP) 
represents a major public health problem, given their extensive multidrug resistance profiles and 
primary role in causing healthcare-associated infections. This phenomenon has largely been contributed 
by strains of Clonal Group (CG) 258, mostly of clade II, which in some areas represent the majority of 
KPC-KP isolates. Here we have characterized a newly discovered lytic Podoviridae, named ϕBO1E, 
targeting KPC-KP strains of clade II lineage of CG258. Genomic sequencing revealed that ϕBO1E 
belongs to the Kp34virus genus (87% nucleotide identity to vB_KpnP_SU552A). ΦBO1E was stable over 
a broad pH and temperature range, exhibited strict specificity for K. pneumoniae strains of clade II of 
CG258, and was unable to establish lysogeny. In a Galleria mellonella infection model, ϕBO1E was able 
to protect larvae from death following infection with KPC-KP strains of clade II of CG258, including one 
colistin resistant strain characterized by a hypermucoviscous phenotype. To our best knowledge ϕBO1E 
is the first characterized lytic phage targeting K. pneumoniae strains of this pandemic clonal lineage. As 
such, it could be of potential interest to develop new agents for treatment of KPC-KP infections and for 
decolonization of subjects chronically colonized by these resistant superbugs.
Resistance to antibiotics that for decades were successfully employed to treat bacterial infections has reached 
an alarming level, and we are increasingly challenged by multidrug resistant (MDR) or extremely drug resistant 
(XDR) pathogens for which very few effective therapeutic alternatives remain available1, 2. This phenomenon has 
become so widespread and worrisome that some international organizations forecast, for the 21th century, the 
advent of a post-antibiotic era in which even common infections could be very difficult if not impossible to man-
age3, 4. In addition, as a result of globalization and increasing international mobility, antibiotic-resistant micro-
organisms tend to disseminate rapidly through different countries and, sometimes, evolve into real pandemics.
One of the most worrisome resistant pathogens undergoing pandemic dissemination is represented by 
Klebsiella pneumoniae producing KPC-type carbapenemases (KPC-KP), which very frequently show an MDR 
or even an XDR phenotype, including last resort molecules such as colistin. KPC-KP have spread rapidly and 
became endemic in several countries (e.g. USA, China, Taiwan, Israel, Greece, Italy and Colombia), where they 
are now a major cause of healthcare-associated infections correlated with high morbidity and mortality rates5–10.
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The pandemic diffusion of KPC-KP was largely contributed by isolates belonging to few sequence types (STs), 
commonly ST11, which is the most prevalent KPC-KP detected in Asian countries (particularly in China and 
Taiwan)11, 12, and ST258 and variants thereof (e.g. ST512, ST554 and ST1879), collectively included in Clonal 
Group 258 (CG258), that experienced a wider dissemination7. Recent studies demonstrated that strains of ST258 
are hybrid clones originated by a number of large genomic recombination events that gave rise to two major 
clades (clade I and clade II), characterized mainly by different capsule polysaccharide (CPS) gene clusters13–15. 
Clade II strains contribute to the majority of ST258 and of other STs of CG258 causing outbreaks reported in 
several regions including USA, Italy, South America, Israel and Greece14, 16–20.
Bacteriophages, which in the pre-antibiotic era were successfully used for the treatment of bacterial infections, 
were recently reevaluated to fight some infections, especially those sustained by MDR bacteria. The present work 
describes the isolation and characterization of a newly discovered lytic bacteriophage able to specifically lyse 
strains of K. pneumoniae of CG258 clade II, which is of potential interest to develop new bacteriophage-derived 
agents against KPC-KP.
Results
Isolation and preliminary characterization of phage ϕBO1E. Phage ϕBO1E was isolated in 
September 2013 from the wastewater system of a large tertiary-care teaching hospital located in central Italy, 
where KPC-KP have been endemic since 2011. Screening of untreated wastewaters for the presence of phages 
able to lyse the K. pneumoniae ST258 clade II test strain KKBO-1 resulted in several plaques that differed in 
size, all surrounded by a hazy halo zone, suggesting the ability by these phages to produce soluble, polysaccha-
ride-degrading enzymes21. Three plaques, characterized by different morphology, were purified and amplified for 
further analysis, as described in the methods section. The restriction analysis of phage DNA obtained from the 
three selected preparations with HindIII and BamHI showed an identical profile, suggesting that the phages were 
identical or very similar to each other, and that their genomes were made by a double-stranded DNA molecule of 
approximately 40–45 Kb. One phage was selected for further characterizations and named ϕBO1E.
ΦBO1E genome sequencing and analysis. High-throughput DNA sequencing of the whole phage 
genome and resolution of the 5′- and the 3′-ends performed by Sanger sequencing showed that the ϕBO1E 
genome was 43,865 bp long, with a GC content of 53.8% and two direct repeats of 224 bp located at the 5′- and 
3′-ends.
Bioinformatic analysis revealed 59 open reading frames (ORF) (Supplementary Table S1), all encoded on the 
same DNA strand (Fig. 1). Comparison with phages genomes deposited in the International Nucleotide Sequence 
Database Collaboration (INSDC) databases revealed that ϕBO1E is a newly discovered bacteriophage most closely 
related with the K. pneumoniae vB_KpnP_SU552A phage (overall nucleotide identity, 87%), a member of the 
Podoviridae family, Autographivirinae subfamily22. Similar to vB_KpnP_SU552A, ϕBO1E encoded a single sub-
unit RNA polymerase, a common characteristic among members of the Autographivirinae subfamily, retained 
the same predicted host and phage promoters as well as a putative rho-independent transcriptional terminator, 
and was characterized by a lysis module composed by spanin-, holin- and endolysin-encoding genes located next 
to each other at the 3′-end of the phage genome. Altogether, these findings suggested that ϕBO1E belongs to the 
newly proposed genus Kp34virus, recently approved by the International Committee on Taxonomy of Viruses22, 23.
Electron microscopy. Results of analysis performed with transmission electron microscopy (TEM) showed 
that ϕBO1E has morphological features typical of the members of the family Podoviridae and order Caudovirales, 
characterized by a head of icosahedral symmetry with a diameter of approximately 50 nm and a short tail of 
Figure 1. Comparison of the ϕBO1E genome with KP34, the type phage of the Kp34virus genus, and with 
vB_KpnP_SU552A, the closest homologous deposited in public nucleotide databases. For each phage the 
corresponding accession numbers and the size in Kb are reported on the left. Long terminal repeats (LTR) are 
indicated by red squares.
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8–10 nm (Fig. 2). This result was consistent with the estimated size of the genome, considering that Podoviridae 
generally have a genome of about 38–45 Kb.
Determination of ϕBO1E bacterial host range. Results from spot tests, carried out with a collection 
of 82 clinical strains of different clonal lineages and capsular types of K. pneumoniae (Supplementary Table S2) 
demonstrated that ϕBO1E has a unique lytic specificity towards strains belonging to clade II of CG258 (e.g. 
ST258, ST512, ST554 and ST1879) and characterized by a CPSKKBO-4/wzi154-type capsular gene cluster, all of 
which were lysed (n = 43). Strains having different CPS (n = 39), including those of ST258 clade I (CPSKK207-
2/wzi29-K41-type), were not sensitive to the action of the phage particles (Supplementary Table S2). The ability of 
ϕBO1E to exclusively lyse CG258 clade II strains, but not those of CG258 clade I, suggests that the cell structures 
recognized by the phage are components of the capsular polysaccharide, since the main difference between the 
two clades is the production of a different type of CPS13, 14.
Sensitivity of ϕBO1E to temperature and pH. Results of experiments performed to assess stability of 
phage particles to temperature and pH demonstrated that ϕBO1E was stable within a wide range of conditions. 
In particular, a notable decrease of the infective capacity ( ≥ 2 log) was observed only after incubation at pH < 4 
or > 9 (Fig. 3a), or after incubation at a temperature ≥ 50 °C for at least 60 minutes (Fig. 3b). These results demon-
strated that ϕBO1E is more stable to temperature than previously described phages of the Kp34virus genus, which 
after 10 minutes at 60 °C exhibited a remarkable decrease in titer22.
Determination of phage life cycle. Plaques of ϕBO1E on the indicator strain KKBO-1 showed a clear 
appearance, with no colonies growing inside the halos, suggesting a lytic nature of the phage. To assess the 
Figure 2. Transmission electron micrograph of phage ϕBO1E negatively stained with uranyl acetate. The bar 
indicates 50 nm.
Figure 3. (a) Influence of pH towards the infection ability of ϕBO1E. Phage suspensions were incubated for 
1 hour at the different pH values indicated by diamonds. (b) Effect of temperature towards the infection ability 
of ϕBO1E. Results obtained with different temperatures, and times of incubations are shown. In both cases data 
are the mean of three independent experiments. Vertical black bars represent one standard deviation.
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possibility of lysogenization, bacterial cells were infected for two rounds with ϕBO1E at increasing multiplicity 
of infection (MOI), as described in the methods section. The cells which survived this exposure were confirmed 
to be phage-resistant because PCR screening with primers specific to the ϕBO1E depolymerase gene yielded no 
amplicons. Altogether these results demonstrated that cells were not ϕBO1E lysogens and that the phage is unable 
to lysogenize its K. pneumoniae host.
One-step growth experiments. Results of burst-size experiments, reported in Fig. 4, showed that the 
phage is characterized by a relatively short latency period (approximately 10 minutes). The period of increase 
of the phage progeny was about 20 minutes before a plateau level is reached at about 30 minutes. The computed 
burst-size was of ≈300 phage particles per infected cell.
Protection from infection in the G. mellonella infection model. To verify the possible in vivo effi-
cacy of ϕBO1E in protecting against infection, the G. mellonella wax moth larvae model was employed. Larvae 
were injected with suspensions of two well characterized KPC-KP strains of the CG258 clade II, KKBO-1 and 
KP04C6224, 25. The former strain is a representative of the major KPC-KP clone circulating in Italy during the 
early phases of the epidemic17, while the latter is a representative of ST512, which emerged subsequently and cur-
rently is one of the most prevalent KPC-KP clones circulating in Italy16. The latter strain is also colistin resistant 
and exhibits a hypermucoviscous phenotype25.
In the G. mellonella model, both strains exhibited a very similar lethal dose 50% (LD50) (KKBO-1, log LD50: 
6.02 ± 0.09 CFU; KP04C62, log LD50: 6.1 ± 0.05 CFU)25, 26. Experiments of phage protection, performed with a 
tenfold LD50 bacterial challenge (107 CFU), revealed that treatment with ϕBO1E was overall capable of protecting 
Figure 4. One-step growth curve of bacteriophage ϕBO1E. Ratios between PFU and the number of infected 
bacterial cells at different times are shown. Data are the mean of three independent experiments. Vertical black 
bars represent one standard deviation.
Figure 5. Kaplan–Meier survival curves of Galleria mellonella larvae infected with 107 cells of KKBO-1 (a) or 
KP04C62 (b) and treated with phage ϕBO1E at a Multiplicity of Infection (MOI) of 10 or 100 at 30 minutes 
post-infection. Results obtained with control larval groups with the same amount of bacterial cells but not 
treated with phage are also shown. Abbreviations are as follow: PBS, phosphate buffered saline; SM, Salt 
Medium.
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G. mellonella from lethal infection (Fig. 5), even if with differences between the two strains. In fact, with KKBO-1 
differences in mortality rates obtained with MOI 10 was not significant (difference of 14% at 72 h, p = 0.4698), 
while a significant protection was observed using an MOI of 100 (difference of 34% at 72 h, p = 0.0023) (Fig. 5a). 
Conversely, with KP04C62 significant protection was observed with both MOIs (Fig. 5b; difference at 72 h of 
43%, p < 0.0001 and 35%, p < 0.0001 with MOI 10 and 100, respectively). The reasons for this difference remain 
unknown. Possible explanations could be: i) the effect of the phage is easier to observe with KP04C62 because lar-
vae die faster or ii) a reduction of the capsule-mediated virulence of the KP04C62 strain connects to the activity 
of the phage virion-associated depolymerase.
Discussion
The advent of antibiotic resistance crisis, with the global dissemination of bacterial pathogens which are resistant 
to most of the available therapeutic options, has renewed the interest for alternatives to antimicrobial compounds. 
The use of lytic bacteriophages as antibacterial agents had been considered in the early 1900s27, and then largely 
abandoned in favor of antibiotics. Recently however phages, or components thereof, have been reconsidered with 
interest as potential antibacterial agents28–30. Advantages of bacteriophages and their components include activity 
against antibiotic resistant bacteria and targeting of a very narrow-spectrum of infecting pathogens, with minimal 
impact on the resident microbiota.
The ϕBO1E phage described in this work is a newly discovered lytic bacteriophage of the Podoviridae family 
able to specifically lyse CG258 KPC-KP of clade II. To the best of our knowledge this report constitutes the first 
example of a lytic phage that specifically targets this lineage. Indeed, other bacteriophages against KPC-KP of the 
Podoviridae and Myoviridae families have been previously described, but their target specificity was not investi-
gated31, 32.
The phage described in this work is characterized by a number of favorable features, such as a notable stability 
to a wide range of pH and temperatures, a strict lytic nature, and the absence in its genome of genes encoding 
potential toxins. These features provide a strong rationale for the possible use of this phage or proteins thereof 
against KPC-KP strains belonging to the CG258 clade II lineage.
Indeed, KPC-KP of CG258 were shown to be among the major drivers for the KPC-KP pandemic, with a 
predominance of clade II strains14, 16, 20. Under these circumstances, the lytic bacteriophage described in this work 
could be of relevant interest as a tool for decolonization of mucosal surfaces or even for the treatment of some 
infections and it could be used, alone or in phage-cocktails, to treat patients according to protocols of personal-
ized medicine33, 34.
The efficacy of ϕBO1E in reducing mortality of G. mellonella larvae infected by KPC-KP of CG258 clade II 
supports a potential utility of this phage for the above mentioned applications, although further experiments 
using different MOIs, times of phage administration and animal hosts (e.g. mouse model) will be necessary to 
confirm this hypothesis.
The specificity of ϕBO1E for this clade suggests that the phage recognizes specific structures exposed on the 
capsular polysaccharide, given the fact that the major difference between the ST258 clades is the expression of 
distinct CPS and that it was recently demonstrated that strains of both CG258 clades express an identical lipopol-
ysaccharide, termed D-galactan III35. The characterization of the molecular targets recognized by ϕBO1E will be 
of paramount importance both to elucidate the infection process of the phage and also to understand the mecha-
nisms leading to resistance to infection, and will be the subject of future investigations. In addition, it would also 
be interesting to test phages related to ϕBO1E for their host-spectrum against CG258 strains.
Materials and Methods
Bacterial strains. The clinical isolate KKBO-1, a previously characterized KPC-KP strain of ST258 clade II14, 24, 
was used as host for phage isolation and propagation. The same strain, along with the clinical isolate KP04C62, a 
KPC-KP strain of ST512 clade II that was also colistin-resistant and expressed an RmpA-independent hypermu-
coviscous phenotype, were used in the G. mellonella infection experiments.
Phage isolation. Bacteriophage ϕBO1E was recovered from untreated hospital wastewaters by using the 
top-agar (lysogeny broth (LB) with 0.7% agar (Oxoid, Hampshire, UK)) overlay method and KKBO-1 as indi-
cator strain, as previously described23 with some modifications. Briefly, 40 ml of wastewaters were centrifuged 
at 3,850 × g at 25 °C for 10 minutes. The supernatant was then filtered sequentially through 0.45 µm and 0.22 µm 
filters and diluted 1:100 in sterile ddH2O. An aliquot of 100 µl of this dilution was then used in the top-agar 
overlay experiment. Three rounds of infection and picking of isolated plaques were performed to obtain pure 
bacteriophage suspensions.
Determination of the host spectrum. The ability of ϕBO1E to target different clones of K. pneumoniae 
was assessed by the spot test technique, using 82 previously characterized KPC-KP clinical strains (Supplementary 
Table S2), as previously described36.
Large-scale production of bacteriophage suspensions. Amplification of bacteriophage ϕBO1E was 
performed as follows. An overnight (O/N, corresponding to 12–18 hours) culture of KKBO-1 in LB broth, con-
centrated to 1/10 of its initial volume in salt medium (SM) buffer37 (final volume 200 µl), was mixed with 100 µl 
of a bacteriophage suspension with a titer of 108 PFU/ml. After incubation for 30 minutes at 37 °C, 5 ml of molten 
top-agar were added and the obtained mixture was poured onto an LB agar (LBA) plate. Ten LBA plates were pre-
pared and, following an O/N incubation at 37 °C, 4 ml of SM buffer were added to each plate. Subsequently, after 
2 hours of incubation at room temperature (RT) with gentle shaking, the top-agar layer together with SM buffer 
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were recovered using a scraper. The obtained mixture was finally centrifuged, and the supernatant was decanted, 
filtered through 0.22 µm filter and stored at 4 °C.
Electron microscopy. A bacteriophage suspension containing ≈1012 PFU/ml, obtained by centrifugation 
at 25,000 × g for 60 minutes of 10 ml of the mixture from large-scale production of the phage, followed by resus-
pension of the pellet in 100 μl of SM buffer (pH = 7.5), was used for electron microscopy analysis. Preparations 
of bacteriophages particles were processed by standard negative stain38, and observed by a FEI Tecnai 12 (FEI, 
Eindhoven, The Netherlands) TEM fitted with an Osis Morada 2X4 K CCD camera (Olympus, Shinjuku, Tokyo, 
Japan). In detail, 10 μl of the concentrated phage suspension were let to adsorb on a carbon-coated matrix and 
then stained with 2% uranyl acetate for 15 seconds. The grid was subsequently washed 2 times with ddH2O, air 
dried and imaged by TEM.
Sensitivity to physical agents. Stability of ϕBO1E at different temperatures was determined by diluting 
phage particles to a final concentration of ≈109 PFU/ml in a final volume of 1 ml of SM buffer. The aliquots were 
incubated at 25 °C (control), 37 °C, 40 °C, 50 °C and 60 °C, for 10, 20, 40 and 60 minutes. After incubation, the 
phage suspensions were titrated. Stability of ϕBO1E at different pH values was determined by diluting phage par-
ticles to a final concentration of 5 × 108 PFU/ml in SM buffer previously brought to different pH values using 1 M 
NaOH or 1 M HCl, to create a pH range from 3 to 11 with intervals of 1 unit. Phage suspensions were incubated 
for 60 minutes at 25 °C and then titrated. Assays for the determination of the stability to temperature and pH were 
made in triplicate and the reported values are the mean of the observations ± standard deviation.
Determination of burst-size. The burst-size of the ϕBO1E phage, representing the average number of 
phages released by each bacterium after the lysis, was determined as follows. The indicator strain KKBO-1 was 
inoculated in 5 ml of LB and the inoculum was grown under aerobic conditions at 37 °C until the exponential 
phase of growth (OD600 = 0.3–0.4). An aliquot of 1 ml of the inoculum was then centrifuged at 13,000 × g for 
5 minutes and the pellet was resuspended in 1 ml of SM buffer. To 0.9 ml of this suspension 0.1 ml of the phage 
lysate at a concentration of 1 × 107 PFU/ml was added, in order to achieve an MOI of 0.01. The mixture was 
incubated for 10 minutes in a water-bath at 37 °C with shaking, centrifuged at 13,000 × g for 4 minutes at RT and 
resuspended in 1 ml of SM buffer to remove any non-adsorbed phages. This preparation was then diluted 1:10,000 
in LB medium (10 ml) and incubated in a water-bath at 37 °C. Aliquots of 0.1 ml were sampled after 10, 20, 25, 
30, 40, 50, 60 and 70 minutes. Each aliquot was added to 4.5 ml of top agar, mixed, poured onto an LBA plate and 
incubated O/N at 37 °C. The latency period was defined as the time between infection (excluding the 15 minutes 
of pretreatment) and the shortest incubation time allowing the production of phages39. The burst-size was cal-
culated as the ratio between the number of phage particles released at the plateau level and the initial number 
of infected bacterial cells. Experiment was performed three times and the reported values are the mean of the 
observations ± standard deviation.
Lysogeny verification. To verify the tentative temperate nature of the isolated phage, exponentially growing 
cultures of KKBO-1 in LB broth were infected with phages at an MOI of ~1 and incubated at 37 °C with shaking 
at 200 rpm for 24 hours. The infected culture was then diluted 1:100 in LB broth and phage stock suspension 
was added at an MOI > 1 × 104. After 1 hour of incubation at 37 °C with shaking at 200 rpm, 0.1 ml were plated 
on LBA and incubated O/N at 37 °C, thus allowing the growth of presumptive ϕBO1E lysogen cells. Nine single 
colonies were picked and isolated in pure cultures. Resistance against ϕBO1E infection was tested by spotting 5 µl 
of the phage stock suspension (corresponding to 5 × 107 PFU) on LB agar plates overlaid with 4.5 ml top-agar 
containing the presumptive ϕBO1E lysogens. Obtained colonies were re-identified at the species level, inves-
tigated by multiplex PCR assay for cps genotyping14 and subjected to PCR amplification using primers target-
ing the ϕBO1E depolymerase gene (CDS59_F 5′-ATGAATTTAGTAAAAGCAAAGTATCCG-3′ and CDS59_R 
5′-CTAGAAAGCTGCCTGGGTATC-3′).
DNA isolation and restriction endonuclease analysis. Extraction of the phage genomic DNA was 
performed using the Wizard® DNA Clean-Up System (Promega, Madison, WI, USA), following manufacturer 
recommendations. The exact determination of phage genomic DNA concentrations was carried out using a 
NanoDrop apparatus (Nanodrop Technologies Inc., Wilmington, USA), following the instructions provided by 
the manufacturer. Phage DNA preparations were digested with HindIII and BamHI restriction endonucleases 
(New-England Biolabs, MA, USA) for 8–10 hours. Restriction fragments were separated by electrophoresis in 
0.75% agarose gel, stained with ethidium bromide and visualized under ultra-violet light to roughly estimate the 
genome size.
Genome sequencing. The genome of ϕBO1E was sequenced using a MiSeq instrument (Illumina Inc., San 
Diego, CA, USA) and a paired-ends approach (2 × 250 bp) with the kit Illumina Nextera™. Characterization of 
the ends of the phage genome was performed by direct Sanger sequencing of bacteriophage DNA, using the prim-
ers BO1E_2 F (5′-TTGACTACGTCGGGATAGGC-3′) and BO1E_1 R (5′-AGCACTAGCGATAGCCAGTG-3′), 
as described elsewhere40.
Bioinformatic analysis. Reads obtained by high-throughput sequencing were trimmed usingDynamic-
Trim.plscript with a h value of 30 and assembled using the ABySS software41, 42. A single contig of 43.8 Kb was thus 
obtained and annotated using the RAST web-service43. Automatic annotation was manually reviewed by BLASTP 
analysis against Refseq proteins deposited in INSDC databases. Conserved protein domains were searched for 
by using the web based CD-Search tool44, and results were filtered to remove non-specific hits. Putative host 
and phage promoters, and rho-independent transcriptional regulators were annotated by comparison with the 
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closest homologs deposited in the INSDC databases: KP34 (Accession number: NC_013649), vB_KpnP_SU503 
(Accession number: KP708985), vB_KpnP_SU552A (Accession number: KP708986), NTUH-K2044-K1-1 
(Accession number: AB716666) and F19 (Accession number: KF765493).
G. mellonella phage therapy assay. Larvae of G. mellonella were obtained from Sa.gi.p (Sa.gi.p, Ravenna, 
Italy) and used after one O/N incubation at 14 °C. Larvae were inspected to select candidates weighing approxi-
mately 450–600 mg for the phage therapy assay. G. mellonella larvae were surface-disinfected with a cotton swab 
dipped in 70% ethanol (Sigma-Aldrich) and injected with 10 μl of inoculum containing 107 cells of K. pneumoniae 
KKBO-1 or K. pneumoniae KP04C62 into the larval haemolymph behind the last proleg, by using a 30-gauge 
syringe (Hamilton, Reno, NV). Bacterial suspensions were prepared in 10 mM phosphate buffered saline (PBS) 
pH 6.5. At 30 minutes post-infection, a group of larvae was injected at the same site, but on the opposite side to the 
bacterial injection, with 10 μl of a ϕBO1E preparation at a concentration to obtain an MOI of 10 or 100. A total 
of 10 larvae was used for each condition. Positive (larvae infected with K. pneumoniae KKBO-1 or KP04C62 and 
treated with SM buffer) and two negative control groups (one group injected with SM buffer only and one group 
injected with phage suspension only) were also included. Larvae were placed into Petri dishes and incubated at 
35 ± 2 °C in the dark, in humidified atmosphere, with food, and daily examined for pigmentation and mobility. 
Time of death was recorded at 24, 48 and 72 hours. For each experiment, the injected inoculum was checked 
by plating serial dilutions and enumerating colonies after 12–16 hours of incubation at 37 °C. Five independent 
experiments were performed for each different bacterial inoculum/phage titer combination. Data from inde-
pendent experiments were pooled and the protection of larvae from death by ϕBO1E was assessed by log-rank 
(Mantel-Cox) test. p values < 0.05 were considered statistically significant. Statistical analyses were performed 
using GraphPad Prism software (GraphPad Software, Inc., La Jolla, USA).
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